Mohacsy's Safe Portfolio Member Forum

[dexprs]

10:11 ET - Drug-stock indexes may be week as the likes of Gilead (GILD) and Lilly (LLY) down 20%+ this year, but Fitch sees a brighter outlook for the industry from a credit perspective. "The good pace of new-drug approvals is expected to continue during 2017, with a particular focus on biologic agents," it notes while raising its outlook to stable. Fitch acknowledges the "intensifying debate around drug pricing," but notes US regulatory risk is less under a Trump administration. ([e-mail]; @Loftus)